Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
November 5, 2015 4:01 PM EST
SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced its unaudited financial results for the third quarter
ended September 30, 2015.
ACADIA reported a net loss of $38.9 million, or $0.39 per common share,
for the third quarter of 2015 compared to a net loss of $24.8 million,
or $0.25 per common share, for the third quarter of 2014. Net losses for
the third quarters of 2015 and 2014 included $9.2 million and $3.9
million, respectively, in non-cash stock-based compensation expense.... More
